Circle Pharma Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
53
- Latest Deal Type
-
Series E
- Latest Deal Amount
-
$92.5M
- Investors
-
24
Circle Pharma General Information
Description
Developer of macrocycle-based therapeutics designed to treat cancer and other serious diseases by targeting previously difficult-to-treat proteins. The company offers a proprietary macrocycle drug development platform that enables cell-permeable and orally bioavailable therapies, enabling biopharmaceutical developers to target cyclins and other cancer-related proteins.
Contact Information
Website
www.circlepharma.comCorporate Office
- 169 Harbor Way
- South San Francisco, CA 94080
- United States
Corporate Office
- 169 Harbor Way
- South San Francisco, CA 94080
- United States
Circle Pharma Timeline
Circle Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series E) | 16-Sep-2026 | $92.5M | Completed | Clinical Trials - Phase 1 | ||
| 8. Later Stage VC (Series D) | 10-Jan-2025 | Completed | Clinical Trials - Phase 1 | |||
| 7. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 6. Later Stage VC (Series C) | 22-Mar-2022 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series B) | 17-Mar-2020 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC (Series A1) | 02-Dec-2018 | Completed | Clinical Trials - Phase 1 | |||
| 3. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 | ||||
| 2. Later Stage VC (Series A) | 25-Apr-2017 | $3.81M | $3.81M | Completed | Clinical Trials - Phase 1 | |
| 1. University Spin-Out | 01-Jan-2012 | Completed | Startup |
Circle Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E 2 | ||||||||
| Series E 1 | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A 1 | 18,740,255 | $0.001000 | $0.04 | $0.49 | $0.49 | 1x | $0.49 | 1.95% |
| Series A | 5,108,742 | $0.001000 | $0.04 | $0.49 | $0.49 | 1x | $0.49 | 0.53% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Circle Pharma Comparisons
Industry
Financing
Details
Circle Pharma Competitors (39)
One of Circle Pharma’s 39 competitors is Orbis Medicines, a Venture Capital-Backed company based in Frederiksberg, Denmark.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Orbis Medicines | Venture Capital-Backed | Frederiksberg, Denmark | ||||
| IDEAYA Biosciences | Formerly VC-backed | South San Francisco, CA | ||||
| Amunix Pharmaceuticals | Formerly PE-Backed | South San Francisco, CA | ||||
| Vividion Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Xenetic Biosciences | Corporation | Framingham, MA |
Circle Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Circle Pharma Patents
Circle Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025226861-A1 | Cyclin inhibitors | Pending | 24-Apr-2024 | ||
| WO-2025226862-A1 | Cyclin inhibitors | Pending | 24-Apr-2024 | ||
| AU-2024275520-A1 | Cyclin inhibitors | Pending | 19-May-2023 | ||
| EP-4712969-A1 | Cyclin inhibitors | Pending | 19-May-2023 | ||
| US-20240408169-A1 | Cyclin inhibitors | Pending | 19-May-2023 | A61K38/12 |
Circle Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Circle Pharma Investors (24)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| RA Capital Management | Asset Manager | Minority | ||
| Mission BioCapital | Venture Capital | Minority | ||
| Eli Lilly and Company Foundation | Limited Partner | Minority | ||
| Euclidean Capital | Family Office | Minority | ||
| Hartford Healthcare Endowment | Limited Partner | Minority |
Circle Pharma FAQs
-
When was Circle Pharma founded?
Circle Pharma was founded in 2012.
-
Where is Circle Pharma headquartered?
Circle Pharma is headquartered in South San Francisco, CA.
-
What is the size of Circle Pharma?
Circle Pharma has 53 total employees.
-
What industry is Circle Pharma in?
Circle Pharma’s primary industry is Drug Discovery.
-
Is Circle Pharma a private or public company?
Circle Pharma is a Private company.
-
What is the current valuation of Circle Pharma?
The current valuation of Circle Pharma is .
-
What is Circle Pharma’s current revenue?
The current revenue for Circle Pharma is .
-
How much funding has Circle Pharma raised over time?
Circle Pharma has raised $305M.
-
Who are Circle Pharma’s investors?
RA Capital Management, Mission BioCapital, Eli Lilly and Company Foundation, Euclidean Capital, and Hartford Healthcare Endowment are 5 of 24 investors who have invested in Circle Pharma.
-
Who are Circle Pharma’s competitors?
Orbis Medicines, IDEAYA Biosciences, Amunix Pharmaceuticals, Vividion Therapeutics, and Xenetic Biosciences are some of the 39 competitors of Circle Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
